Organon delivers impactful medicines and solutions for a healthier every day
We are an approximately $6.5 billion global healthcare company with an impactful portfolio of medicines and products across a range of therapeutic areas. Our global business is comprised of three core pillars, Women’s Health, Biosimilars, and Established Brands. This includes over 60 products across a range of areas including reproductive health, heart disease, dermatology, allergies and asthma. And we bring these important medicines around the world, with an international footprint that serves people in more than 140 markets.
Organon’s global expertise is in reproductive health, with a focus on contraception and fertility and a commitment to expand into areas that address other diseases and conditions that impact her health throughout her life.
We will go beyond the traditional areas of focus in women’s health to address conditions that are unique to women and that disproportionately affect her or have an especially heavy burden. Beyond our product offerings, access to our medicines is equally important. As we work to reach more women around the world, we are also dedicated to ensuring that she has access to our treatments. With more than 140 therapies that are being investigated by multiple companies across the women’s health industry, our goal is to add value by identifying and advancing the most promising opportunities for women.
Our global portfolio of 49 medicines spans several areas including cardiovascular disease, respiratory conditions, non-opioid pain management and dermatology.
These trusted brands have a long history across serious diseases and conditions and even after loss of exclusivity for some of these products, they continue to have an impact around world. We believe these medicines, combined with our strong manufacturing capabilities and broad geographic footprint, will allow us to continue delivering on the full potential of our Established Brands portfolio while also realising growth opportunities in select markets through indication expansions and collaborations. This diverse set of products are a critical driver of Organon’s growth that will enable us to invest in new opportunities across Organon’s portfolio.
Our Biosimilars products are available in various parts of the world and treat a variety of serious diseases and conditions. Organon’s expertise is in the commercialisation of these products, bringing them to more people around the world.
We believe that Biosimilars are an important option that can help reduce the cost pressure on the healthcare system, and help more people access biologic therapies. Our goal for the future is to build from our strong foundation by broadening the reach of our portfolio into new geographies, while expanding our offerings through new collaborations and into new disease areas.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Organon Pharma (UK) Limited (Tel: 02081 593593). By clicking the above link you will leave the Organon website and be taken to the MHRA website.